Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

0.5449 -0.0250 (-4.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 263,717
Open 0.5317
Bid (Size) 0.5300 (6)
Ask (Size) 0.5994 (20)
Prev. Close 0.5699
Today's Range 0.5300 - 0.5605
52wk Range 0.4200 - 2.350
Shares Outstanding 1,362,729,582
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better... 
Via Newsfile
Exposures Product Safety
Adaptimmune Receives Transfer of IND for Lete-cel Program
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma... 
Via Newsfile

Performance

YTD
-67.37%
-67.37%
1 Month
-3.18%
-3.18%
3 Month
-25.89%
-25.89%
6 Month
-44.81%
-44.81%
1 Year
-69.04%
-69.04%

More News

Read More
Adaptimmune Reports Third Quarter Financial Results and Business Update
Via Newsfile
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Via Newsfile
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
Via Newsfile
Analyst Expectations for Adaptimmune Therapeutics's Future
Via Benzinga
Recap: Adaptimmune Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview For Adaptimmune Therapeutics
Via Benzinga
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Via Newsfile
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Via Newsfile
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Via Newsfile
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Via Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Adaptimmune Reports Second Quarter Financial Results and Business Update
Via Newsfile
Exposures Product Safety
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Via Newsfile
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Via Newsfile
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
Via Newsfile
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Earnings Scheduled For May 12, 2023
Via Benzinga
Adaptimmune Reports First Quarter Financial Results and Business Update
Via Newsfile
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
Via Newsfile
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
Via The Motley Fool
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.